Bioblast Pharma

Hope should not be rare

BioBlast Pharma Announces Positive Final Results from HOPEMD Phase 2 Open-Label Clinical Study of Trehalose 90mg/mL IV Solution in Oculopharyngeal Muscular Dystrophy (OPMD)

Thu, 2016-03-10 00:00 -- Bioblast Pharma

NEW HAVEN, Conn., March 10, 2016 (GLOBE NEWSWIRE) — BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced today that Colin Foster, President and CEO, will provide a corporate overview and business update at the 28th Annual ROTH Conference, taking place in Orange County, California, March 13-16, 2016.

Presentation Details:

Title: 28th Annual ROTH Conference
Date: Tuesday, March 15, 2016
Time: 8:00am Pacific Time
Location: Ritz Carlton, Orange County, California


About BioBlast
BioBlast Pharma is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. The Company’s portfolio consists of product candidates with the potential to address unmet medical needs for incurable diseases. The BioBlast platforms are based on an in depth understanding of the disease-causing biological processes, and potentially offer solutions for several diseases that share the same biological pathology. For more information please visit the Company’s website,, the content of which is not incorporated herein by reference.

Matthew P. Duffy
Managing Director
LifeSci Advisors, LLC
Telephone: 212-915-0685